Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical CEO Resigns

NEW YORK (GenomeWeb News) – Response Biomedical late Friday announced the resignation of its CEO Wayne Kay, effective immediately. Kay also resigned as a director of the Vancouver, British Columbia-based diagnostics company.

Peter Thompson will serve as executive chairman and interim CEO, and Reponse Bio has retained an executive search firm to seek a permanent CEO.

Kay's resignation came two days after the firm announced a 17 percent increase in its second-quarter revenues. During the quarter, though, its submission to the US Food and Drug Administration for 510(k) clearance of its NTproBNP assay for the diagnosis of heart failure on its Ramp 200 platform had been turned down.

Kay had previously served as CEO of venture capital firm Kleiner Perkins Caufield & Byers, and was president and CEO of Quidel.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.